Literature DB >> 23330678

Improvement in efficacy of DNA vaccine encoding HIV-1 Vif by LIGHT gene adjuvant.

Jiani Du1, Xiaoyu Wu, Fengying Long, Jiejun Wen, Wenli Hao, Ran Chen, Xiaobo Kong, Min Qian, Wenzheng Jiang.   

Abstract

DNA vaccine can induce the prolonged immune responses against the encoded antigen with the appropriate adjuvant. To study the immunogenicity of the HIV-1 vif DNA vaccine in inducing the humoral and cellular immune responses and the immunoadjuvant effect of LIGHT, which is a member of TNF superfamily and can stimulate the proliferation of naïve T cells as a co-stimulatory molecule, DNA vaccine plasmid pcDNA-Vif was constructed by inserting HIV-1 vif gene into the downstream of CMV promoter in eukaryotic expression vector pcDNA3.1(+). In vitro expression of HIV-1 Vif in pcDNA-Vif-transfected HeLa cells was confirmed in transcriptional and protein level by RT-PCR and Western blot, respectively. After BALB/c mice were injected muscularly with DNA vaccines for three times, the specific immune responses were analyzed. The data showed that anti-Vif antibody response, Vif-specific T cell proliferation, and CTL activities were induced in the mice that were inoculated with HIV-1 vif DNA vaccine plasmid. Interestingly, stronger humoral and cellular immune responses were detected in mice that were immunized with plasmid pcDNA-Vif and pcDNA-LIGHT together compared to the single immunization with plasmid pcDNA-Vif alone. Together, the results of the study suggest that candidate HIV-1 DNA vaccine can elicit HIV-1 Vif-specific immune responses in mice and that LIGHT plays the role of immunoadjuvant in co-immunization with DNA vaccine.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23330678      PMCID: PMC3578369          DOI: 10.1089/vim.2012.0073

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  31 in total

1.  LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response.

Authors:  K Tamada; K Shimozaki; A I Chapoval; Y Zhai; J Su; S F Chen; S L Hsieh; S Nagata; J Ni; L Chen
Journal:  J Immunol       Date:  2000-04-15       Impact factor: 5.422

2.  Hypermutation of HIV-1 DNA in the absence of the Vif protein.

Authors:  Denise Lecossier; Francine Bouchonnet; François Clavel; Allan J Hance
Journal:  Science       Date:  2003-05-16       Impact factor: 47.728

Review 3.  DNA vaccines.

Authors:  H L Robinson; C A Torres
Journal:  Semin Immunol       Date:  1997-10       Impact factor: 11.130

Review 4.  DNA vaccines.

Authors:  J J Donnelly; J B Ulmer; J W Shiver; M A Liu
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

5.  LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator.

Authors:  D N Mauri; R Ebner; R I Montgomery; K D Kochel; T C Cheung; G L Yu; S Ruben; M Murphy; R J Eisenberg; G H Cohen; P G Spear; C F Ware
Journal:  Immunity       Date:  1998-01       Impact factor: 31.745

6.  Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially.

Authors:  Franco Pissani; Delphine C Malherbe; Harlan Robins; Victor R DeFilippis; Byung Park; George Sellhorn; Leonidas Stamatatos; Julie Overbaugh; Nancy L Haigwood
Journal:  Vaccine       Date:  2012-06-27       Impact factor: 3.641

7.  A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation.

Authors:  B S Kwon; K B Tan; J Ni; K O Oh; Z H Lee; K K Kim; Y J Kim; S Wang; R Gentz; G L Yu; J Harrop; S D Lyn; C Silverman; T G Porter; A Truneh; P R Young
Journal:  J Biol Chem       Date:  1997-05-30       Impact factor: 5.157

8.  First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response.

Authors:  R R MacGregor; J D Boyer; K E Ugen; K E Lacy; S J Gluckman; M L Bagarazzi; M A Chattergoon; Y Baine; T J Higgins; R B Ciccarelli; L R Coney; R S Ginsberg; D B Weiner
Journal:  J Infect Dis       Date:  1998-07       Impact factor: 5.226

Review 9.  DNA vaccines: a novel approach to immunization.

Authors:  E F Fynan; R G Webster; D H Fuller; J R Haynes; J C Santoro; H L Robinson
Journal:  Int J Immunopharmacol       Date:  1995-02

10.  HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.

Authors:  Kim Stopak; Carlos de Noronha; Wes Yonemoto; Warner C Greene
Journal:  Mol Cell       Date:  2003-09       Impact factor: 17.970

View more
  5 in total

1.  Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD).

Authors:  Brian M Olson; Eric S Bradley; Thomas Sawicki; Weixiong Zhong; Erik A Ranheim; Jordan E Bloom; Viswa T Colluru; Laura E Johnson; Brian T Rekoske; Jens C Eickhoff; Douglas G McNeel
Journal:  Prostate       Date:  2017-02-09       Impact factor: 4.104

2.  Expression and Characterization of Two DNA Constructs Derived from HIV-1-vif in Escherichia coli and Mammalian Cells.

Authors:  Fatemeh Zamani; Azam Bolhassani; Sepideh Shahbazi; Ahmad Faghih; Seyed Mehdi Sadat
Journal:  Avicenna J Med Biotechnol       Date:  2021 Jul-Sep

Review 3.  Suppression of APOBEC3-mediated restriction of HIV-1 by Vif.

Authors:  Yuqing Feng; Tayyba T Baig; Robin P Love; Linda Chelico
Journal:  Front Microbiol       Date:  2014-08-26       Impact factor: 5.640

4.  DNAVaxDB: the first web-based DNA vaccine database and its data analysis.

Authors:  Rebecca Racz; Xinna Li; Mukti Patel; Zuoshuang Xiang; Yongqun He
Journal:  BMC Bioinformatics       Date:  2014-03-19       Impact factor: 3.169

5.  Comparison of HIV-1 Vif and Vpu accessory proteins for delivery of polyepitope constructs harboring Nef, Gp160 and P24 using various cell penetrating peptides.

Authors:  Kimia Kardani; Atieh Hashemi; Azam Bolhassani
Journal:  PLoS One       Date:  2019-10-31       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.